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ABSTRACT
Inﬂammation of the brain and the consequential immunological responses play pivotal roles in
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral
sclerosis, and frontotemporal dementia (FTD). Microglia, the resident macrophage cells of the brain,
have also emerged as key players in neuroinﬂammation. As primary human microglia from living
subjects are normally not accessible to researchers, there is a pressing need for an alternative
source of authentic human microglia which allows modeling of neurodegeneration in vitro. Several
protocols for induced pluripotent stem cell (iPSC)-derived microglia have recently been developed
and provide unlimited access to patient-derived material. In this present study, we give an overview
of iPSC-derived microglia models in mono-culture and coculture systems, their advantages and limi-
tations, and how they have already been used for disease phenotyping. Furthermore, we outline
some of the gene engineering tools to generate isogenic controls, the creation of gene knockout
iPSC lines as well as covering reporter cell lines which could help to elucidate complex cell interac-
tion mechanisms in the microglia/neuron coculture system, for example, microglia-induced synapse
loss. Finally, we deliberate on how said cocultures could aid in personalized drug screening to iden-
tify patient-speciﬁc therapies against neurodegeneration. STEM CELLS 2019;00:1–7
SIGNIFICANCE STATEMENT
Microglia and neuroinﬂammation are at the center in current research efforts to identify targets to
ﬁght various neurodegenerative diseases. However, the tragic failures of many recent drug candidates
in clinical trials showed that the results from mouse models have only limited transferability to the
clinical setting. Human iPSC-derived neuron/microglia cocultures emerge as an authentic human, pre-
clinical tool, for drug candidate validation. Testing a series of drugs on big patient cohorts will allow
substratifying of patients into drug responders and nonresponders whereas this study foresees a
future where complex patient-speciﬁc cocultures are used in personalized medicine.
INTRODUCTION
Microglia are the resident macrophages of the
brain. Most models of neurodegenerative dis-
eases used in preclinical research are murine
models which allow for the study of microglia
either directly within the brain, in organotypic
slice cultures, or as primary microglia upon iso-
lation from fresh brain tissue or from ex vivo
cocultures with astrocytes. From the various avail-
able mouse disease models, there is, therefore,
theoretically, unlimited availability of primary or
cultured mouse microglia. The drawback, how-
ever, is the limited translation of mouse results to
human pathologies, seen because of the differ-
ences in the key modulators of their respective
neuroinﬂammatory pathways [1] and differential
expression of risk genes [2].
A meaningful analysis of freshly isolated micro-
glia from healthy or patient’s brain is extremely dif-
ﬁcult since the material is very limited and the
tissue obtained post-mortem or during brain sur-
gery often comes with artifacts or comorbidities.
Most research in human microglia is, therefore,
done with cultured fetal or adult primary microglia.
These cultures although have been shown not to
be a very authentic model for the microglia in the
brain environment and loose microglial transcrip-
tome signature within the ﬁrst hours ex vivo cul-
ture [3].
Brain samples of patients with neurodegen-
erative disease are extremely rare and nor-
mally only accessible post-mortem. However, in
order to understand the initiation of pathology
or for screening for potential drugs that reduce
the pathology, material from presymptomatic
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patients, or samples from early stages of the disease would be
most valuable. Induced pluripotent stem cells (iPSCs) can be
derived from many easily accessible tissue sources of patients
such as skin ﬁbroblasts or blood. Many protocols have been
developed to differentiate iPSCs to the key players in neurode-
generation [4] (i.e., neurons, microglia, astrocytes, and oligo-
dendrocytes) and for adult onset neurodegenerative diseases,
we can expect that in many cases those iPSC-derived cell types
represent the presymptomatic stage of the disease displaying
physiological deﬁcits preceding neuronal death. Furthermore,
it is known that maturing iPSC to adult neurons takes more
than 100 days of differentiation [5].
Blood monocytes are easily accessible, and protocols exist
that claim to skew them toward a microglia identity [6–8].
Later transcript analysis, however, revealed that these blood
monocyte-derived microglia differ signiﬁcantly from microglia
in the brain [9]. Adult blood monocytes derive from myeloblas-
tosias proto-oncogene, transcription factor (MYB)-dependent
hematopoietic stem cells (HSCs) in the bone marrow, whereas
microglia originate from MYB-independent yolk sac derived
fetal macrophages that invade the human brain around embry-
onic day 31 until closure of the blood–brain barrier (BBB) pro-
liferate locally and are not replaced by other macrophages in
healthy individuals [10]. Therefore, blood monocyte-derived
microglia are likely to resemble the blood monocyte-derived
cells found in the brain after stroke. These cells adapt micro-
glial morphology but differ both functionally and at transcrip-
tome level from resident microglia [11]. Therefore, we believe
that, in order to obtain a near-authentic microglia model, one
should faithfully mimic the microglial ontogeny and provide a
neuronal environment. The cells should differentiate in a MYB-
independent manner to yolk sac-derived fetal macrophages and
be allowed to invade into a neuronal environment, where they
mature and adapt ramiﬁed microglial morphology and where
they can display the full set of microglial functions which are
present only upon interaction with neurons.
IPSC MICROGLIA PROTOCOLS
The ﬁrst protocols for human embryonic stem cell (hESC)-
derived macrophages used cocultures with cell lines, complex
cytokine cocktails, and laborious puriﬁcation steps to enrich for
CD34+ HSCs and macrophage progenitor colonies [12, 13] and it
is unknown if those protocols follow MYP dependent or MYB-
independent myeloid differentiation. Later, the James lab devel-
oped a simple protocol for the production of macrophages from
pluripotent stem cells without the use of additional feeder cells
during differentiation, using only interleukin-3 (IL-3) and macro-
phage colony stimulation factor (M-CSF) to drive myelopoiesis,
thereby yielding a pure macrophage population without the
need for additional puriﬁcation steps [14]. They adapted the
protocol to feeder-free iPSCs with fully deﬁned conditions and
were able to take weekly yields from their macrophage factories
for more than 6 months [15]. By showing that the macrophage
differentiation of MYB knock out (KO) iPSCs was unchanged,
they demonstrated that those cells are MYB-independent yolk
sac derived embryonic macrophages, hence their macrophages
are indeed ideal microglia progenitors [16]. Furthermore, they
showed that in coculture with cortical neurons those cells show
microglia typic ramiﬁcations, movement, cytokine release, and
transcriptome [17].
Furthermore, protocols for the production of hESC/iPSC-
derived microglia have since been developed. Beutner et al.
described the production of mouse iPSC microglia emerging
from neuronal cultures [18] and Almeida et al. were ﬁrst to
claim they produced human iPSC microglia with an apparently
similar protocol, yet methodological details have not been pro-
vided [19]. Those microglia have characteristics of an immor-
talized microglia cell line, which allows fast expansion for large
scale experiments. They are not, however, suitable for long-
term cocultures and they do not show a convincing microglia
transcriptome signature [3]. Schwartz et al. has used human
iPSC microglia in three-dimensional (3D) coculture with neu-
rons to study neurotoxicity but a further characterization of
the microglia in those brain organoids was regrettably not pro-
vided [20]. Several protocols with extensive characterization of
human iPSC-derived microglia have been published recently
[17, 21–27]. Abud et al. initially use low oxygen during differen-
tiation and need sorting of HSCs before going through a two-step
maturation protocol to obtain mature microglia, importantly,
they successfully transplanted their iPSC-derived microglia into
mouse brains. Takata et al. showed the importance of neuron
microglia interaction for the microglial maturation, most of their
work, however, was performed with mouse iPSC microglia and
only proof of principle data was shown for human iPSC micro-
glia. McQuade from the same lab published a faster protocol
using STEMdiff Hematopoietic Kit with conﬁdential composition
to obtain HSCs, then they do a fast ﬁnal differentation without
IL-3 in the medium, those iPSC microglia were also sucessfully
transplanted in mouse brains [26]. Pandya et al. are coculturing
iPSC-derived HSCs with astrocyes to obtain iPSC microglia [23];
we assume that this protocol releases microglia most similar to
primary microglia released from mixed glial cultures. Ormel
et. al found that microglia innately develop within iPSC-derived
cerebral organoids and showed that those microglia perform
similar as primary human microglia in functional assays [27].
Their cerebral organoid protocol is omitting non-neuronal linage
suppression. From their data, it remains unclear to us if the ﬁrst
microglia progenitors originate within cerebral organoids or invade
the cerebral organoids but originate from yolk sac organoids
present in a mixed organoid culture, hence, if their results are
incompatible with the hypothesis of yolk sac derived origin of
microglia that invade the brain. iPSC themselves show rela-
tively high expression of growth factors SCF, VEGF, BMP4,
IL34, CSF1, and CSF2 [28], which are used in most of the desc-
ribed iPSC microglia protocols. It was shown previously that
adding SCF, VEGF, and BMP4 to initiate HSC differentiation is
optional but increases its efﬁciency [15]. Haenseler et al., who
are using the James lab’s MYB-independent macrophages, have
the simplest and most user-friendly of those protocols [17].
They use only IL-3 and M-CSF to drive myelopoiesis and pure
microglia precursors can be collected repeatedly from the mac-
rophage factory supernatants, without the need for any sorting
procedure. Those precursors can then be matured to microglia
in mono-culture or in coculture with neurons in medium supple-
mented with IL-34 and GM-CSF. Furthermore, the James lab
macrophages are by now the only ones proven to derive MYB-
independent by using MYB KO iPSC lines [16]. Haenseler et al.
designed coculure conditions for the use as an Alzheimer’s dis-
ease (AD) model, maturing the iPSC-derived cortical neurons for
©2019 The Authors. STEM CELLS published by
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65 days after neuronal induction, when they have formed func-
tional synapses and show electrical activity [17, 29] and impor-
tantly release all the major β-peptides Aβ 38/40/42 [30]. Microglia
precursors are cocultured for the last 2 weeks of the neuron
differentation and adapt the ramiﬁed morphology after approxi-
mately 1 week of coculture. Recently, their macrophage precur-
sors were shown to integrate in brain organoids and survive
integration into the organoids without supplementation of
external growth factors [25]. Xiang et al. use the James lab pro-
tocol for production of microglia precursors and then changed
to the microglia medium described by Abud et al. for ﬁnal mat-
uration in mono-cultures [31]; their iPSC microglia show similar
expression of key microglia markers as primary microglia, unfor-
tunatly a direct comparison to the James lab microglia is not
provided.
We conclude that all those protocols provide iPSC-derived
microglia, but only direct side-by-side comparisons of the microglia
from those protocols could answer which produces the most
authentic microglia regarding transcriptome and functional assays.
Interestingly, we see in many protocols that iPSC microglia have
higher expression of some of the microglia markers than the cul-
tured primary microglia, which might be explained by loss of
microglia markers in primary microglia cultures. Although most
protocols use IL-3 and M-CSF in their diffferentations medium to
drive myelopoiesis, it is currently unknown if using additional
growth factors improve microglia signature. The optimal choice of
growth factors and the presence of serum in the maturation/assay
medium should be made dependent on the planned assays. In
future protocols, we also expect cocultures with speciﬁc neuron
subtypes for optimal disease modeling, for example, dopaminergic
neurons for Parkinson’s disease (PD) models.
DISEASE PHENOTYPING IN DIFFERENT HUMAN MICROGLIA
MODELS
The James lab iPSC-derived macrophages/microglia have been
used in various disease relevant setups in the James lab or in
other labs with minor variations of the protocol. They were used
as model for HIV integration [32] and entry [33] and used as a
gene therapy model for the primary immunodeﬁciency chronic
granulomatous disease (CGD), where patients lack functional
NADPH oxidase, which is responsible for reactive oxygen species
(ROS) production [34]. CGD iPSCs were corrected with CRISPR/
Cas9 footprintless gene editing [35], which fully restored ROS
production in iPSC macrophages. Such patient iPSC lines would
be an invaluable tool to investigate effects of partial and full loss
of NADPH oxidase function in neuroinﬂammation, for example,
to conﬁrm the results obtained in rat primary neuron-glia cul-
tures, which show neurotoxicity depended on phagocytosis of
α-synuclein and activation of NADPH oxidase with production of
ROS [36]. The James lab iPSC macrophages were used for a tran-
scriptional analysis comparing lipopolysaccharide (LPS) induced
inﬂammation between peripheral blood mononuclear cell-derived
macrophages and iPSC-derived macrophages [37] and to assay the
heterogeneity of LPS induced inﬂammatory response of iPSC mac-
rophages with single cell RNA sequencing [38]. Furthermore, they
were compared with primary mouse macrophages for Escherichia
coli phagocytosis [39] and were used to elucidate the role of
FRMD8 in tumor necrosis factor α (TNF-α) shedding pathway [40].
Neurological disease relevant phenotypes have been described in
these iPSC macrophages from patients with Gaucher’s disease
with GBA mutations, where reduced ROS production and impaired
chemotaxis was observed [41, 42]. In PD patients with synuclein
alpha (SNCA) triplication, the macrophages showed accumulation
of α-synuclein and reduced phagocytosis [43]. LRRK2 mutant mac-
rophages showed alterations in Mycobacterium tuberculosis infec-
tion [44] and TREM2 mutants showed defects in TREM2 processing
[25] and defects in phagocytosis of apoptotic neurons [45]. Interest-
ingly, TREM2 with the R47H mutation is aberrantly spliced only in
mice but not human primary- and iPSC-microglia [31].
The Neumann lab showed reduced progranulin secretion in
iPSC-derived microglia from a frontotemporal dementia (FTD)
patient [46]. APOE4 variant of mono-culture microglia, differenti-
ated following the Muffat protocol, have been shown to have
impared amyloid-β42 clearance [47]. Although in a human tri-
culture system with SV40 immortalized microglia, iPSC astrocytes
and iPSC neurons, activation in response to Swedish mutant
β-amyloid precursor protein (APP) neurons, which secrete high
levels of Aβ, was demonstrated [48].
Independent of which differentiation protocol is used, onemust
distinguish between mono-culture, two-dimensional (2D) neuron
coculture protocols, and 3D culture/brain organoids. An overview of
advantages and disadvantages of those models and published as
well as suggested disease phenotyping assays is given (Table 1).
Depending on the research question, cocultures indeed can be
mixes of iPSC-derived cell-types and human or animal primary cells
or cell-lines, this can also include the transplantation of human iPSC
microglia to animal models. For preclinical testing of antineurode-
generation drugs, it is also crucial to show that the drug can cross
the BBB. These tests are currently best done in animal models, how-
ever, human primary cell [51] and iPSC BBB organoid [50] models
have been developed.
GENETIC ENGINEERING OF IPSC
Perhaps one of the bigger advantages of iPSCs is that they can
be cultured long-term without loss of genome integrity and
pluripotency. Patient iPSCs are, therefore, a theoretically unlim-
ited source of material for disease modeling or cell replacement
therapies. iPSCs are well accessible for genetic manipulations
whereas postmanipulation clonal lines can be selected and qual-
ity controlled before differentiation. Retroviruses and adeno-
associated viruses (AAV) are a good tool for the correction of
loss of function mutations by overexpression of the malfunc-
tional protein when correct gene dosage is irrelevant [52, 53].
CRISPR/Cas9, Zinc ﬁnger, and TALEN technology can be
used for gene editing to introduce a transgene to a deﬁned
place in the genome. Introducing the transgenes to save har-
bor sites such as AAVS1 leads to phenotypic correction [49].
But any of those technologies can also be used to create gene
knockout lines or gene correction by directly targeting the
gene of interest. CRISPR/Cas9 was used for footprintless gene
correction [35] and tagging of endogenously expressed genes
is possible [54]. It has also been used in patient iPSCs to
remove additional gene copies such as the very rare SNCA
gene triplication [55], which causes early onset PD and to
remove surplus GGGGCC repeats in C9orf72 that cause amyo-
trophic lateral sclerosis (ALS) [56].
Reliable disease phenotyping can be carried out with
several patients who carry the same mutation but who are
not siblings and, therefore, have different genetic backgro-
unds. Alternatively, an isogenic pair can be created either by
www.StemCells.com ©2019 The Authors. STEM CELLS published by
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correction of a patient iPSC line to obtain an isogenic control
line, or by introducing the patient mutation into a healthy con-
trol line to reproduce the rare patient phenotype (Fig. 1A).
Using isogenic pairs has the big advantage that two lines are
the minimal requirement for an experiment. Working with spo-
radic disease patient, iPSCs are perhaps the most challenging, as
heterogenous phenotypes are expected and high patient num-
bers are needed to be able to stratify patients postanalysis (sex,
age, biomarker, severity of the disease, look for compound het-
erozygous SNPs, etc.).
Reporter iPSC lines have many possible applications in mono-
cultures and in the coculture system (Fig. 1B). Retroviruses can
be used to create reporter lines that express ﬂuorescent proteins
under speciﬁc promoters to identify cells of interest, for exam-
ple, thyroxine hydroxylase as a marker of dopaminergic neurons
[57], or nuclear factor “kappa-light-chain-enhancer” of activated
B-cells (NF-κB) to identify activated microglia [58]. The expres-
sion of tagged proteins allows easy visualization and tracking of
the protein of interest in live cells. However, retrovirally intro-
duced genes are often silenced in iPSCs or during differentiation
to the cell of interest. This can be prevented by using silencing
resistant promoters to drive transgene expression, with a pro-
moter combined with sequences that prevent silencing such as
the UCOE sequence [52, 59] or by introducing a selection cas-
sette and apply constant selection pressure (such as puromycin,
neomycin, zeocin) as previously done for RFP iPSC-derived micro-
glia before adding them to the neuronal cocultures [17]. Another
option is to gene-edit the endogenous gene locus to coexpress
a ﬂuorescent reporter or directly introduce a tag such as the
short FLAG tag to visualize the endogenous protein [60]. Fur-
thermore, modeling tools are inducible promoters allowing to
switch genes on or off in the differentiated cells [61].
USING MICROGLIA/NEURON COCULTURES FOR DISEASE
PHENOTYPING AND DRUG SCREENING
Recently, it was demonstrated in a mouse model that neurode-
generation through synapse loss could occur even if the neu-
rons were kept unperturbed but by removing a gene (in this
case, TARDP/TDP-43) speciﬁcally in microglia suggesting a key
role for microglia in neurodegeneration and thus emphasizing
the need for human iPSC microglia–neuron cocultures to study
how this synapse loss could be prevented in patients [62].
A screen for drugs that prevent synapse loss in the iPSC
coculture system could be based on reporter lines. Neurons
with ﬂuorescently tagged synapses could be used to assay
synaptotoxicity combined with microglia containing an activa-
tion reporter. As a ﬁrst step, one would have to identify synap-
totoxic conditions to recapitulate microglia-induced synapse
loss in the cocultures. The second step would be to screen for
reagents that interrupt the microglia/neuron interaction lead-
ing to the induced synaptotoxicity and stop the synapse loss.
Such a coculture system combined with fully automated high-
Table 1. Comparison of different iPSC microglia models
Model Advantages (+)/limitations of the model (−)
Published disease phenotyping/suggested
phenotyping assays
Microglia
Mono-culture
+ Monocultures are suitable to study intrinsic defects
of the microglia
+ Scalable for high throughput screens
+ Cell lysis for protein and RNA isolation directly in
well
− Many microglia functions are related to interactions
with neurons and, therefore, can exclusively be
observed in cocultures
Reduced progranulin secretion in microglia of FTD
patients [46]
SNCA triplication with reduced phagocytosis of
zymosan and upregulation of
cytokines/chemokines [43]
APOE4 with reduced uptake of amyloid-β42 [47]
GBA mutants with reduced ROS production and
impaired chemotaxis [41, 42]
Restored macrophage function after gene therapy
[35, 49]
TREM2 T66M, W50C mutants with reduced
phagocytosis of apoptotic neurons [45] and
R47H showed altered TREM2 splicing in mouse
but not human microglia [31]
Microglia/neuron
Coculture 2D
+ Microglial scanning of neuronal environment
observed
+ Transcriptome closer to primary microglia
+ Focus on key players of neurodegeneration
− Additional cell types are involved in
neurodegeneration (astrocytes, oligodendrocytes)
− Protein and RNA isolation needs elaborate
separation of microglia and neurons (MACS, FACS)
Microglia morphology (ramiﬁed vs. amoeboid),
microglia migration and
Inﬂammatory response in coculture, which is not
sum of mono-cultures [17]
Microglia induced neurotoxicity
Microglia induced synapse loss
Microglial clearance of neuron derived toxic
products such as amyloid-β and α-synuclein
Microglia addition to 3D cultures
and brain organoids
+ Authentic cell interactions
+ Triculture system is well deﬁned
+ Triculture system can be imaged in 96-well plate
+ Cerebral organoids can include BBB models [50]
− Long maturation times of organoids
− Organoids are hard to image
− Low throughput
− Inguided heterogenous brain organoid are variable
in cell composition (reproducibility)
TREM2 mutant microglia have unchanged invasion
of brain organoids [25]
Microglia activation by Swedish APP neurons [48]
Microglia migration/integration into brain
Complex interactions of different brain cell types
astrocyte/microglia/neuron/oligodenrocyte
crosstalk upon stress/damage
Microglia proliferation/microgliosis and astroglyosis
upon stress/damage
Microglia related BBB damage
Abbreviations: iPSC, induced pluripotent stem cell; FTD, frontotemporal dementia; BBB, blood–brain barrier.
©2019 The Authors. STEM CELLS published by
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content-imaging and automated image analysis would allow
for high-throughput drug screens.
Probably, more relevant for drug screens are patient/gene-
engineered iPSC microglia/neuron cocultures, where the ﬁrst
step is to identify a well-reproducible disease phenotype. Ide-
ally, one can conﬁrm that this phenotype is resolved in isogenic
controls/or by using other gene therapy approaches. Once a
phenotype is identiﬁed, the system allows dissecting to under-
stand which cells are the origins of the phenotype and, there-
fore, contain the potential drug target. This dissection can be
done with mono-cultures of neurons and microglia but also by
match/mismatch experiments with healthy control and disease
microglia and neurons in a coculture system (Fig. 1C). Once phe-
notypes are identiﬁed, the system is ideal for drug screening.
Furthermore, patients could be stratiﬁed according to pheno-
types, and the response to the drugs could be tested in sub-
groups or in a real personalized medicine approach.
Match/mismatch experiments would also answer which
cells have to be targeted by cell replacement therapies or by
gene therapy approaches.
POTENTIAL CLINICAL USE OF GENE-EDITED IPSC
Gene therapy approaches to treat neurodegenerative diseases
typically use AAV vectors that are injected directly into the
brain [53, 63, 64]. For example, an AAV9 gene therapy vector
successfully corrected Gaucher’s disease phenotypes in fetal
Figure 1. Induced pluripotent stem cell (iPSC) tools and their suggested use in the microglia/neuron coculture model. (A): iPSCs deriva-
tion from healthy controls or patients. On iPSC level, mutations can be introduced to healthy control cells or removed from patient cells
without otherwise changing the genetic background of the iPSC line, thus obtaining ideal isogenic control lines. (B): Examples for the use
of ﬂuorescent reporters in iPSC microglia/neuron cocultures. (B1): Neurons (red) and microglia (green), which express cytosolic ﬂuores-
cent proteins allow the identiﬁcation of corresponding cells in life imaging experiments. (B2): Tissue-speciﬁc expression of ﬂuorescent
proteins can be used to identify subtypes of cells in the culture (e.g., TH for dopaminergic neurons). (B3): Tissue-speciﬁc expression of
ﬂuorescent proteins can show activation status of microglia (e.g., NF-κB). (B4): Tagged proteins can show the position of a protein
(e.g., PSD95 to mark the synapses). (C): Strategy to identify the disease-causing cell type by combining matched and mismatched control
and patient neurons/microglia and comparison to mono-cultures to test if cells produce the respective phenotype on their own.
www.StemCells.com ©2019 The Authors. STEM CELLS published by
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and newborn GBA KO mice and has been demonstrated to be
able to transduce neurons in a macaque brain after in utero
delivery of the gene therapy vector [53].
Implanting autologous gene-edited iPSC-derived cells into
patients open new therapeutic possibilities. Human iPSC-derived
dopaminergic neurons were recently shown to have great thera-
peutic beneﬁt as cell-based therapeutics in a primate model of
PD [65]. The tools to edit-iPSC are there, as we know iPSC-derived
microglia successfully integrated in murine brains [21, 26] and
GMP grade iPSC-derived HSCs with the needed quality controls
are under development [66].
The obvious gene therapy approach is to correct the patient
iPSC lines back to a healthy gene variant. But one could also go
a step further and create enhanced iPSC-derived cells, for exam-
ple, with improved clearance for speciﬁc toxic peptides or
reduced neurotoxic repertoire. Our own lab results show that
tweaking a gene in microglia could alter the outcomes that
result in neurodegeneration [50] and thus it is totally conceiv-
able to alter iPSC-derived microglia to have properties that can
be exploited therapeutically for neuroprotection.
CONCLUSION
Recently, several convincing protocols for the generation of
human iPSC-derived microglia have been published [17, 21–24].
The MYB-independent ontogeny of those microglia has so far
only been convincingly demonstrated by the protocol developed
in the James lab which uses MYB KO iPSCs [16]. The most
authentic microglia morphologies were observed in cocultures
with neurons, respectively, after injection into mouse brains,
which also correlated with the most microglia like transcriptome
[17, 24]. However, most disease relevant phenotyping is so far
done in mono-culture microglia. For many phenotyping assays,
mono-cultures are an acceptable and economically plausible choi-
ce, but to investigate the role of microglia interactions with neu-
rons in neurodegenerative diseases, the coculture of microglia
with neurons is a prerequisite. There are now several models of
2D and 3D coculture available that would allow assaying neuro-
toxicity at different levels of complexity. The major advantages
of iPSC-derived microglia as compared with primary human
cells are the theoretically unlimited availability of patient mate-
rial as well as the possibility to create isogenic controls and
to engineer reporter cells designed speciﬁcally to your assay
readouts. Match/mismatch experiments can identify the origin
of neurotoxicity and thus tells us which cell type has to be tar-
geted by drugs, gene therapy, or cell replacement therapies.
AD, PD, and FTD/ALS are all complex and heterogeneous dis-
eases where patients substratify in drug responses. Drug candi-
date testing in iPSC cocultures using cells from big patient
cohorts promise to substratify the patients according to their
drug responses. But we also foresee a future were complex
coculture systems are used in a real personalized medicine
approach to test the drug response of each individual patient
before onset of treatment.
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